Abstracts (HTML) List of Authors

Tamura, K

Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer

Taran, FA

Comparison of therapy benefit from standard anti-HER2-directed approaches in metastatic breast cancer (MBC) between initially-HER2 positive patients and patients initially HER2-negative with switch to HER2-positive

Tasoulis, MK

Identifikation von Brustkrebspatientinnen mit einer pathologischen Komplettremission in der Brust nach neoadjuvanter Systemtherapie mittels intelligenter vakuum-assistierter Biopsie

Teistler, M

SonoGame

Teixeira, FCOB

Die Expression von Hedgehog-Signalweg assoziierten Genen beeinflusst die Prognose von Brustkrebspatientinnen

Telli, ML

IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)

Tendl-Schulz, K

Axillärer Lymphknotenstatus und neoadjuvante Therapie beim HER2-positiven Mammakarzinom

Tesch, H

Comparison of therapy benefit from standard anti-HER2-directed approaches in metastatic breast cancer (MBC) between initially-HER2 positive patients and patients initially HER2-negative with switch to HER2-positive

Testa, L

Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer

The Oncoplastic Breast Consortium (OPBC),

Immediate pre-pectoral implant-based breast reconstruction with or without additional heterologous pocket devices (OPBC-03/POCKET)

Thewes, V

Intraoperative Gewinnung von Frischgewebsproben für molekulargenetische Analysen zwecks individualisierter postneoadjuvanter Therapie

Thill, M

Mesh-pocket supported prepectoral direct-to-implant breast reconstruction: Preliminary results of a prospective analysis
Seltene Patientengruppen in der klinischen Routine: Behandlungs- und Outcomedaten von Patientinnen mit invasiv lobulärem, metastasiertem Mammakarzinom aus der prospektiven, deutschen Registerplattform OPAL
Characteristics of patients with brain metastases from HER2-positive breast cancer
PERFORM: An epidemiological, prospective cohort study for patients with HR+/HER2- advanced breast cancer treated 1st-line with an endocrine-based palbociclib combination therapy in real world in Germany and Austria
Magseed®-guided long-term marking of target lymph nodes in neoadjuvant therapy of early breast cancer patients - experiences in 13 patients
Identification of risk factors in implant-based mesh supported breast reconstruction - results of the 2years follow up analysis of the PRO Bra Trial
AXSANA (Axillary Surgery After Neoadjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy: preliminary data

Thomas, P

A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)

Thomé, J

Stem-cell enriched hybrid breast reconstruction and augmentation and its effects on capsular contracture

Thomsen, AR

Hypofraktionierte Re-Bestrahlung in Kombination mit wIRA-Hyperthermie bei lokal rezidiviertem Mammakarzinom: Darstellung einer Fallserie

Thomssen, C

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro - AGO-B-046

Tinfissi, S

Erhöhte Serumzytokine bei Brustkrebs und ihre Auswirkungen auf die Blut-Hirn-Schranke in vitro

Ting, S

The role of Ki67 in involved lymph nodes as a predictive biomarker for response to neoadjuvant chemotherapy in patients with early breast cancer (EBC)

Tischitz, M

Vergleich der immunhistochemischen Ergebnisse zwischen präoperativem Biopsiematerial und Operationspräparat des frühen Mammakarzinoms

Toi, M

Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer
MONARCH 2: subgroup analysis of patients receiving abemaciclib+fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer (ABC)
Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: update from the MONARCH 2 study of abemaciclib plus fulvestrant

Tolaney, S

Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: update from the MONARCH 2 study of abemaciclib plus fulvestrant

Traut, E

Prospektive, multizentrische Registerstudie zur Evaluation der gezielten, axillären Dissektion (TAD) nach Clipmarkierung von klinisch suspekten Lymphknoten beim primären Mammakarzinom (SenTa)
Studiennetzwerk Rhein-Ruhr: eine erfolgreiche Kooperation zur Verbesserung der Patientenversorgung

Tropschuh, K

Drug-induced liver injury durch Abemaciclib

Tryakin, A

Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer

Tüchler, A

Risk perception in healthy women with a family history of breast cancer: results of a prospective observational study

Turner, N

A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)